Positron emission tomography and colorectal cancer

British Journal of Surgery

Volumn 88, Issue 2, 2001, Pages 176-189

  Arulampalam, T H A ^a   Costa, D C ^a   Loizidou, M ^a   Visvikis, D ^a   Ell, P J ^a   Taylor, I ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINO ACID C 11; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY TC 99M; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FLUOROURACIL F 18; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3 IN 111; MONOCLONAL ANTIBODY BW 431 26 TC 99M; RADIOPHARMACEUTICAL AGENT; THYMIDINE; THYMIDINE C 11; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; IMMUNOSCINTIGRAPHY; LIVER METASTASIS; LYMPH NODE METASTASIS; MEDICAL INSTRUMENTATION; MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOBIOLOGY; RECURRENT CANCER; REVIEW; TECHNIQUE;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035130408     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2001.01657.x     Document Type: Review

References (127)

1. Cancer in the European Community and its member states
2. Cancer statistics, 1997
3. Colon Cancer
4. Surgical management of locally recurrent rectal cancer
5. Patterns of recurrence after curative resection of carcinoma of the colon and rectum
6. Imaging of colorectal carcinoma
7. Colorectal cancer. Radiologic staging
8. Detection of colorectal liver metastases: Comparison of laparotomy, CT, US, and Doppler perfusion index and evaluation of postoperative follow-up results
9. Current follow-up strategies after resection of colon cancer. Results of a survey of members of the American Society of Colon and Rectal Surgeons
10. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer
11. CT of the gastrointestinal tract: Principles and interpretation
12. Colorectal carcinoma evaluation with CT: Preoperative staging and detection of postoperative recurrence
13. Magnetic resonance imaging of rectal cancer on the evaluation of preoperative staging and detection of post operative local recurrence
14. Diagnostic value in magnetic resonance imaging of intrapelvic recurrence of rectal carcinoma: Comparison to computed tomography
15. Recurrent rectal cancer and scar: Differentiation with PET and MR imaging
16. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography
17. Increased accumulation of 2-deoxT-2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma
18. On the metabolism of tumours in the body
19. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection
20. Accuracy of endosonography in the staging of rectal cancer treated by radiotherapy
21. Current imaging strategies for colorectal cancer
22. PET in oncology: Will it replace the other modalities?
23. New imaging techniques in colorectal cancer
24. Recurrence of colorectal tumors: PET evaluation
25. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography
26. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
27. On the origin of cancer cells
28. Transport of sugars in tumor cell membranes
29. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes
30. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
31. Enzymology of cancer cells
32. Correlation of increased FDG-uptake and elevated expression of glucose transporter 1 gene in human pancreatic carcinoma
33. Over-expression of facilitative glucose transporter genes in human cancer
34. Distribution of the glucose transporters in human brain tumors
35. Growth factors rapidly induce expression of the glucose transporter gene
36. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat
37. Metabolic trapping as a principle of oradiopharmaceutical design: Some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose
38. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells
39. Influence of the blood glucose concentration on FDG uptake in cancer - A PET study
40. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines
41. Staging recurrent metastatic colorectal carcinoma with PET
42. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy
43. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer
44. Positron emission tomography in the clinical evaluation of metastatic cancer
45. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms
46. Future of positron-emission tomography in oncology
47. How high a level of FDG abdominal activity is considered normal?
48. Radiology in the detection and prevention of colorectal cancer
49. Positron emission tomography for preoperative staging of colorectal carcinoma
50. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer
51. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice
52. Reassessing the role of radiology in Hemoccult screening
53. Diagnosis and staging of colonic tumors by conventional abdominal sonography as compared with hydrocolonic sonography
54. Technical report: Spiral CT pneumocolon for suspected colonic neoplasms
55. Helical CT pneumocolon to assess colonic tumors: Radiologic-pathologic correlation
56. A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps
57. Colonoscopy with computed tomography with volume reconstruction. The results and a comparison with endoscopy and surgery
58. An initial experience with screening for colon polyps using spiral CT with and without CT colography (virtual colonoscopy)
59. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
60. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC)
61. Preoperative short-term radiation therapy in operable rectal carcinoma A prospective randomized trial
62. Resection of liver metastases-when is it worthwhile?
63. CT and MR imaging in the staging of colorectal carcinoma: Report of the Radiology Diagnostic Oncology Group II
64. Importance of endoscopic ultrasonography staging for treatment of rectal cancer
65. Colorectal villous adenoma: Transrectal US in screening for invasive malignancy
66. Preoperative staging of rectal cancer by intrarectal ultrasound
67. Endosonography of pararectal lymph nodes. In vitro and in vivo evaluation
68. Preoperative staging of rectal and colonic cancer
69. The utility of diagnostic laparoscopy for abdominal disorders. Audit of 120 patients
70. Preoperative assessment of the extension of rectal carcinoma: Correlation of MR, surgical, and histopathologic findings
71. Preoperative and postoperative CT staging of rectosigmoid carcinoma
72. Carcinoma of the colon: Detection and preoperative staging by CT
73. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: Comparison with CT
74. The value of immunoscintigraphy for the operative retreatment of colorectal cancer. Limitations of a new diagnostic method
75. Liver metastases
76. Liver tumor imaging: Current concepts
77. Comparison between high-field-strength MR imaging and CT for screening of hepatic metastases: A receiver operating characteristic analysis
78. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584
79. Radioimmunodetection of occult carcinoembryonic antigen-producing cancer
80. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases
81. Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer
82. Metastatic colorectal cancer: Radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody
83. Staging of primary colorectal carcinomas with fluorine- 18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
84. Resection of pelvic recurrence
85. Total pelvic exenteration for locally advanced colorectal carcinoma
86. Metastasectomy
87. Pelvic recurrence of rectal cancer. Options for curative resection
88. Tumor recurrence versus fibrosis in the female pelvis: Differentiation with MR imaging at 1.5 T
89. Recurrent rectal cancer: Diagnosis with MR imaging versus CT
90. Suspected recurrent rectosigmoid carcinoma after abdominoperineal resection: MR imaging and histopathologic findings
91. Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3
92. 99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: First clinical results
93. Immunoscintigraphy of colorectal carcinomas and recurrences with a technetium-99m-labeled monoclonal anti-CEA-antibody (MAB XBW431/26)
94. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study
95. Local recurrence after sphincter-saving resection for rectal and rectosigmoid carcinoma. Value of various diagnostic methods
96. The value of intensive follow-up after curative resection for colorectal carcinoma
97. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
98. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer
99. PET-FDG imaging for follow-up evaluation of treated colorectal cancer
100. Pre-operative staging of colorectal carcinoma using positron emission tomography
101. Clinical application and economic implications of PET in the assessment of colorectal cancer recurrence: A retrospective study
102. Whole-body PET-FDG imaging in diagnosis of recurrent colorectal cancer
103. Detection of recurrent colorectal carcinoma with whole-body FDG PET
104. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
105. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
106. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer
107. Monitoring liver tumor therapy with [18F]FDG positron emission tomography
108. Noninvasive monitoring of tumor metabolism using fiuorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
109. Assessment of response to cancer therapy using fluorine-18- fluorodeoxyglucose and positron emission tomography
110. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
111. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma
112. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma
113. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy
114. Assessment of radiotherapeutic effects on experimental tumors using 18F-2-fluoro-2-deoxy-D-glucose
115. Therapy monitoring of presacral recurrences after high-dose irradiation: Value of PET, CT, CEA and pain score
116. Dosimetry and preliminary human studies of 18F-5-fluorouracil
117. A model for prediction of chemotherapy response to 5-fluorouracil based on the differential distribution of 5-[18F]fluorouracil in sensitive versus resistant lymphocytic leukemia in mice
118. Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion
119. The applications of PET in clinical oncology
120. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma
121. Fluorouracil: Biochemistry and pharmacology
122. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil
123. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group
124. Cost-effectiveness of PET imaging in clinical oncology
125. Analytical decision model for the cost-effective management of solitary pulmonary nodules